目的 观察抗妇炎胶囊联合重组人干扰素α2a治疗慢性宫颈炎的临床疗效。方法 选取2015年7月—2016年6月在武汉商职医院就诊的106例患者为研究对象，随机分为对照组和治疗组，每组各53例。对照组患者睡前阴道深部放置重组人干扰素α2a栓，1粒/次，隔日1次；治疗组在对照组的基础上口服抗妇炎胶囊，3粒/次，3次/d。两组均连续治疗30 d。治疗后，观察两组患者临床疗效，同时比较治疗前后两组患者宫颈修复时间、临床症状缓解时间以及不良反应情况。结果 治疗后，对照组和治疗组的总有效率分别为69.81%、88.68%，两组比较差异具有统计学意义（P< 0.05）。治疗后，治疗组患者宫颈修复和临床症状缓解时间均显著短于对照组，两组比较差异具有统计学意义（P< 0.05）。两组均无明显不良反应发生。结论 抗妇炎胶囊联合重组人干扰素α2a临床疗效确切，组织修复快，不良反应较轻，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of Kangfuyan Capsules combined with recombinant human interferon α2a in treatment of chronic cervicitis. Methods Patients (106 cases) with chronic cervicitis in Wuhan Commercial Workers Hospital from July 2015 to June 2016 were randomly divided into control group and treatment group, and each group had 53 cases. Patients in the control group were were given Recombinant Human Interferon α2a Vaginal Suppositories at bedtime, 1 suppository/time, once every other day. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy was evaluated, and cervical repair time, remission time of clinical symptoms, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P < 0.05). After treatment, cervical repair time and remission time of clinical symptoms in the treatment group were shorter than those in the control group, and there was difference between two groups (P < 0.05). There were no adverse reactions in two groups.Conclusion Kangfuyan Capsules combined with recombinant human interferon α2a has clinical curative effect in treatment of chronic cervicitis with rapid tissue repair and less adverse reactions, which has a certain clinical application value.of clinical application.